IRIS
VIOLA, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.457
NA - Nord America 1.605
AS - Asia 1.299
SA - Sud America 385
AF - Africa 42
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.550
RU - Federazione Russa 1.459
SG - Singapore 617
BR - Brasile 324
CN - Cina 268
IE - Irlanda 242
IT - Italia 227
SE - Svezia 192
HK - Hong Kong 181
FR - Francia 79
DE - Germania 76
VN - Vietnam 74
IN - India 43
GB - Regno Unito 42
CA - Canada 29
PL - Polonia 29
FI - Finlandia 26
AT - Austria 22
AR - Argentina 21
BD - Bangladesh 21
NL - Olanda 18
MX - Messico 16
JP - Giappone 15
ZA - Sudafrica 11
EC - Ecuador 10
ES - Italia 9
TR - Turchia 9
CL - Cile 8
IQ - Iraq 8
PK - Pakistan 8
KE - Kenya 7
UZ - Uzbekistan 7
ID - Indonesia 6
JO - Giordania 6
PH - Filippine 6
VE - Venezuela 6
BE - Belgio 5
CO - Colombia 5
LT - Lituania 5
MA - Marocco 5
NI - Nicaragua 5
PY - Paraguay 5
SA - Arabia Saudita 5
KZ - Kazakistan 4
NO - Norvegia 4
PE - Perù 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
MY - Malesia 3
UA - Ucraina 3
AL - Albania 2
AZ - Azerbaigian 2
BY - Bielorussia 2
EE - Estonia 2
GE - Georgia 2
IL - Israele 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AU - Australia 1
BG - Bulgaria 1
BW - Botswana 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
NP - Nepal 1
RE - Reunion 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.793
Salva come PNG Salva come JPEG
Città #
Moscow 450
Ashburn 352
Singapore 310
Dublin 240
Hong Kong 181
Chandler 169
San Jose 143
Dallas 139
Nyköping 94
Beijing 72
Messina 60
Los Angeles 50
Lauterbourg 39
Princeton 37
Medford 33
The Dalles 33
Munich 31
São Paulo 27
Des Moines 24
Hanoi 22
New York 22
Frankfurt am Main 20
Ho Chi Minh City 20
Orem 20
Redondo Beach 20
Buffalo 19
Chennai 18
Seattle 15
Vienna 15
London 14
Tokyo 14
Ann Arbor 13
Milan 13
Catania 12
Denver 12
Warsaw 12
Amsterdam 11
Atlanta 11
Santa Clara 11
Stockholm 11
Brooklyn 10
Council Bluffs 10
Guangzhou 10
Nuremberg 10
Rome 10
Jinan 9
Lappeenranta 9
Mexico City 9
Curitiba 8
Montreal 8
Rio de Janeiro 8
Tianjin 8
Dearborn 7
Jacksonville 7
Manchester 7
Porto Alegre 7
Turku 7
Amman 6
Boston 6
Campinas 6
Changsha 6
Johannesburg 6
Mumbai 6
Nairobi 6
Nanjing 6
Pozzuolo Martesana 6
San Francisco 6
Shanghai 6
Shenzhen 6
Tashkent 6
Toronto 6
Turin 6
Wilmington 6
Belo Horizonte 5
Brussels 5
Chicago 5
Düsseldorf 5
Hebei 5
Helsinki 5
Houston 5
Jakarta 5
Lahore 5
Managua 5
Phoenix 5
Zhengzhou 5
Baghdad 4
Brasília 4
Cagliari 4
Guayaquil 4
Haikou 4
Hangzhou 4
Palermo 4
Pelotas 4
Pune 4
Santiago 4
Shenyang 4
Vitória da Conquista 4
Addis Ababa 3
Aracaju 3
Bexley 3
Totale 3.166
Salva come PNG Salva come JPEG
Nome #
Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach 203
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project 167
Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study 165
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 157
Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease 153
DWI ratios: New indexes for Crohn's disease activity at magnetic resonance enterography? 149
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 149
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 149
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis 143
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 143
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 142
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study” 139
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study 137
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study 132
Role of IL-33/ST2 Pathway in Inflammatory Bowel Disease: An Overview and Future Perspectives 128
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs? 118
Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research 114
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease 110
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 109
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 109
A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy 105
Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic 105
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches 104
Tissue levels of Tumour Necrosis Factor-alpha as molecular biomarker of inflammation and prediction of sustained treatment response in patients with Ulcerative Colitis. 104
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 101
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases 97
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach 96
Defense mechanisms and inflammatory bowel diseases: a narrative review 95
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 92
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 91
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 91
IL PAZIENTE ANZIANO CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE: OSSERVAZIONI IN UN GRUPPO DI PAZIENTI AMBULATORIALI 91
DWI ratios at MR-Enterography: a new way for inflammation degree assessment in Crohn's disease patients? 90
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results from the SoCOVID-19 Survey 90
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease 88
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 85
Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients 84
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 84
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study 82
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 79
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 78
Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis 76
Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography 75
Ultrasonography tight control and monitoring in crohn's disease during different biological therapies: a multicenter study 71
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center 67
Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency-A Possible Adverse Drug Reaction 65
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD) 65
Corticosteroid use in patients with inflammatory bowel diseases: A real-life sub-analysis of the Italian DICE study 61
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 60
Incident Colorectal Cancer in Inflammatory Bowel Disease 59
Epidemiology and clinical course of late onset inflammatory bowel disease 55
Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature 55
SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 51
Letter: the clinical course of Crohn's disease—the Sicilian experience 44
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease 43
null 40
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study 39
Cardiovascular Risk Assessments and Ultrasound-Assisted Re-Stratification in Patients with Inflammatory Bowel Disease (IBD) 36
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease 35
null 33
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? 32
Standard Therapeutic Approach and New Therapies 29
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 29
Psychological impairment in inflammatory bowel diseases: the key role of coping and defense mechanisms 28
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19 24
The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases 24
TNF-α Quantification in Formalin-Fixed Paraffin-Embedded Tissues as a Predictive Biomarker in Ulcerative Colitis 24
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study 13
Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern 1
Totale 5.982
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.344
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.344
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202142 0 0 0 0 0 0 0 0 0 19 16 7
2021/2022287 5 31 3 2 8 4 14 10 11 74 21 104
2022/2023597 39 65 26 53 29 45 14 28 268 11 13 6
2023/2024256 20 29 36 54 14 23 7 15 0 33 8 17
2024/20251.244 16 21 16 79 60 76 94 194 271 79 133 205
2025/20263.379 156 145 216 227 339 745 474 490 437 150 0 0
Totale 5.982